The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Baseline biomarker analysis and clinical outcomes of the PD-1/TGFßR2 bispecific antibody INCA33890 in patients with non-MSI-H metastatic colorectal cancer (mCRC).
 
Justin Moyers
Consulting or Advisory Role - OncLive/MJH Life Sciences; Pfizer; Replimune
Speakers' Bureau - Curio Science
 
Michelle Kinder
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Rui Hong
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Michael Smith
Employment - Incyte
Stock and Other Ownership Interests - Incyte
Patents, Royalties, Other Intellectual Property - Patents pending for proprietary work at Incyte
Travel, Accommodations, Expenses - Incyte
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare; Genomics testing Cooperative; Outcomes Matter Innovations (OMI)
Consulting or Advisory Role - Incyte
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Sreenivasa Chandana
Leadership - The Cancer & Hematology Centers
Consulting or Advisory Role - AstraZeneca; IPSEN
Speakers' Bureau - Natera
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Cardiff Oncology (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Elevation Oncology (Inst); Exact Sciences (Inst); Genentech/Roche (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Qualigen Therapeutics (Inst); Zymeworks (Inst)
 
Markus Joerger
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
Research Funding - Anaveon; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Immunophotonics; Incyte; Innomedica; Intensity Therapeutics; Lilly; Merck Sharp & Dohme; Novartis; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - travel grants from Roche; travel grants from Sanofi
 
Irene Moreno
Consulting or Advisory Role - BOXER CAPITAL LLC; ELLIPSES PHARMA; Guidepoint Global
Speakers' Bureau - Getthi group
Research Funding - DIGICORE (IDEAL4RWE); FUNDACIÓN INTHEOS
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Armando Santoro
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Incyte; MSD; Pfizer; Sanofi; SERVIER
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Bayer; BeiGene; BMS; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Sandoz; Servier; Takeda
 
Debra Josephs
Stock and Other Ownership Interests - Careology (I); ZoomDoc (I)
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; EUSA Pharma; Iovance Biotherapeutics; Ipsen; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Pfizer
Patents, Royalties, Other Intellectual Property - I declare patents on antibodies for cancer
Travel, Accommodations, Expenses - BMSi; Johnson & Johnson/Janssen
 
Haeseong Park
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo/UCB Japan; Merck
Research Funding - Amgen (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); D3Bio (Inst); Exelixis (Inst); Genentech (Inst); Huoata Bio (Inst); Idience (Inst); Incyte (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Strata Oncology (Inst); Tizona Therapeutics, Inc. (Inst); Yuhan (Inst)
Travel, Accommodations, Expenses - Amgen
 
Massimo Di Nicola
No Relationships to Disclose
 
Tatiana Hernandez Guerrero
No Relationships to Disclose
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics
Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Maria Vieito Villar
Consulting or Advisory Role - BMS; myTomorrows; SERVIER
Speakers' Bureau - Novocure
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Novartis (Inst); Roche; Roche/Genentech (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Travel, Accommodations, Expenses - Roche
Other Relationship - BMS GmbH & Co. KG (Inst); Debiopharm Group (Inst); HUTCHMED (Inst); Incyte (Inst); Mundipharma (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); SERVIER (Inst); Taiho Oncology (Inst)
 
Xiaohan Xu
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Chiara Greggio
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Thomas Karasic
Employment - Incyte
Stock and Other Ownership Interests - Incyte
Honoraria - Merus
Consulting or Advisory Role - Synnovation Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Genentech (Inst); Lilly (Inst); Tempest Therapeutics (Inst); Totus Medicines (Inst); Xencor (Inst)
 
Ruth Plummer
Honoraria - honoraria for advisory boards from AmLo; honoraria for advisory boards from Astex Therapeutics; honoraria for advisory boards from Bayer; honoraria for advisory boards from Bristol-Myers Squibb; honoraria for advisory boards from Cybrexa Benevolent AI; honoraria for advisory boards from Ellipses; honoraria for advisory boards from Genmab; honoraria for advisory boards from Immunocore; honoraria for advisory boards from Incyte; honoraria for advisory boards from Merck Sharp & Dohme; honoraria for advisory boards from Nerviano; honoraria for advisory boards from Novartis; honoraria for advisory boards from Pierre Faber; honoraria for advisory boards from Sanofi Aventis
Consulting or Advisory Role - honoraria for participating as an IDMC member for Alligator Biosciences; honoraria for participating as an IDMC member for AstraZeneca; honoraria for participating as an IDMC member for GSK; honoraria for participating as an IDMC member for Onxeo; honoraria for participating as an IDMC member for Pharmamar; honoraria for participating as an IDMC member for SOTIO Biotech AG
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Research Funding - Incyte (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme